Nycomed Amersham Imaging has announced favorable results from a 12-year study of patients receiving treatment with its OncoSeed brachytherapy iodine-125 seeds. In research presented at the American Urological Association meeting in Atlanta, a follow-up study of early-stage prostate cancer patients treated with OncoSeed demonstrated disease-free survival rates comparable to those reported for patients undergoing radical prostatectomy, according to the Princeton, NJ-based firm. The research also matches data from a 10-year OncoSeed study published in 1998, according to Nycomed Amersham.
By AuntMinnie.com staff writers
May 4, 2000
Copyright © 2000 AuntMinnie.com
